Sunil Rangarajan, MD
Medical Oncology · Birmingham, ALNPI 1124439526
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 22.5%. 2025 is the largest year on record at $2,249, 4.9 times the $458 reported in 2019. That places this record below the midpoint for medical oncology clinicians in AL, where the typical reported total is $5,924.
Across 30 payments — averaging $174.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Incyte Corporation$1K
- AstraZeneca$1K
- Rigel Pharmaceuticals, Inc.$1K
- Amgen$200
- Bristol Myers Squibb$121
- plus $631 from 11 others
Across 224 payments — averaging $2548.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ares Trading SA$405K
- Merck$109K
- Biontech SE$29K
- Janssen Research & Development, LLC$27K
- EMD Serono, Inc.$120
What the payments were for
- Consulting fees$2,63550%
- Speaking & faculty fees$1,00019%
- Grants$2525%
- Food & beverage$73314%
- Education$60712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $1,174 |
| Incyte Corporation | 1 | $1,100 |
| AstraZeneca(2 entities) | 6 | $1,001 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,000 |
| Amgen | 2 | $200 |
| Bristol Myers Squibb | 4 | $121 |
| Eisai Inc. | 1 | $114 |
| Intuitive Surgical | 1 | $109 |
| Tempus AI, Inc | 1 | $92 |
| Seagen Inc. | 1 | $77 |
| Lilly USA, LLC | 1 | $70 |
| Exelixis Inc. | 1 | $35 |
| Beigene USA, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Gilead | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$1,010
- Tavalisse$1,000
- LYNPARZA$525
- LENVIMA$114
- Da Vinci Surgical System$109
How this compares
$5,227 in reported general payments places this provider in the 45th percentile of 30 medical oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 45 | $743,656 |
| InlytaAxitinib | 27 | $499,163 |
| Abiraterone Acetate | 158 | $498,298 |
| JakafiRuxolitinib Phosphate | 28 | $317,185 |
| CabometyxCabozantinib S-Malate | 12 | $307,856 |
| RevlimidLenalidomide | 15 | $199,374 |
| EliquisApixaban | 65 | $74,875 |
| OrgovyxRelugolix | 29 | $74,023 |
| XareltoRivaroxaban | 55 | $57,702 |
| OxycontinOxycodone Hcl | 11 | $15,210 |
| CreonLipase/Protease/Amylase | 14 | $9,885 |
| Oxycodone Hcl | 53 | $1,649 |
| Anastrozole | 59 | $1,447 |
| Prochlorperazine Maleate | 73 | $1,193 |
| Prednisone | 215 | $1,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $1,100 | $317,18528 claims |
| Exelixis Inc.Cabometyx | $35 | $307,85612 claims |
| Bristol Myers SquibbRevlimid | $121 | $199,37415 claims |
| Johnson & JohnsonXarelto | $1,174 | $57,70255 claims |
| Lilly USA, LLCOlanzapine | $70 | $7520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 30 medical oncology providers in Alabama.
Other medical oncology in Birmingham
- Daniel AllendorfBirmingham$2K
- Joelle HamiltonHomewood$361K
- Syed Abbas AliJasper$51K
- Pranitha ProdduturvarMobile$33K
- Johnny NacillaCullman$23K
- Michael GarciaJasper$23K
- John WaplesHuntsville$19K
- Susan BostickTuscaloosa$17K
- Brittany CaseDaphne$17K
- Charles LattuadaAnniston$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.